Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC

R. Kate Kelley, MD
Published: Saturday, Apr 22, 2017



R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma (HCC).

In the advent of immunotherapy in HCC, there has been a renewed interest in determining biomarkers to find patients best suited for this treatment.

Following in the footsteps of other gastrointestinal malignancies, biomarkers like mutation burden may be a useful indicator, Kelley says. It is still too early to know, adds Kelley, as more data need to be collected to make a distinct analysis.
 


R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma (HCC).

In the advent of immunotherapy in HCC, there has been a renewed interest in determining biomarkers to find patients best suited for this treatment.

Following in the footsteps of other gastrointestinal malignancies, biomarkers like mutation burden may be a useful indicator, Kelley says. It is still too early to know, adds Kelley, as more data need to be collected to make a distinct analysis.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x